Analyst Update: Alphabet Inc, Facebook Inc, and Ligand Pharmaceuticals Inc.

Analysts are weighing in on Alphabet Inc (GOOGL), Facebook Inc (FB), and Ligand Pharmaceuticals Inc. (LGND)

Sep 27, 2016 at 1:56 PM
facebook twitter linkedin


Analysts are weighing in on internet issue Alphabet Inc (NASDAQ:GOOGL), social media stock Facebook Inc (NASDAQ:FB), and drugmaker Ligand Pharmaceuticals Inc. (NASDAQ:LGND). Here's a quick roundup of today's brokerage notes on GOOGL, FB, and LGND.

  • Elsewhere, TWTR rival and fellow "FANG" stock FB is 1.1% higher at $128.77 on a $5 price-target hike to $175 at J.P. Morgan Securities -- waters never before charted by the shares. Separately, FB-owned Instagram is reportedly seeing strong adoption among millennials, according to GlobalWebIndex -- with 58% of internet users between the ages of 18 and 32 having an account, up from 41% two years ago. Year-to-date, Facebook Inc stock has marched 23% higher, and its short-term options traders have become increasingly call-skewed. Specifically, the equity's Schaeffer's put/call open interest ratio (SOIR) of 0.48 rests in the low 2nd annual percentile, with calls doubling puts among options expiring in the next three months.
  • Unlike the aforementioned "FANG" stocks, LGND is down sharply -- shedding 11.5% at $100.05, and landing on the short-sale restricted list. Putting the hurt on the shares is news that Amgen, Inc.'s (NASDAQ:AMGN) Kyprolis failed in a Phase 3 study, as Ligand Pharmaceuticals Inc. receives royalties from sales of the multiple myeloma drug. Plus, Roth Capital trimmed LGND's price target to $150 from $151 -- still in never-before-seen territory. The shares are now on track for their lowest close since late March, and analysts could respond with more negative attention. After all, 80% of covering brokerage firms maintain "strong buy" opinions on LGND, with not a single "sell" recommendation to be found.
Don't miss the market's next move! Sign up now for Schaeffer's Midday Market Check
 

If you are not making money with options, you aren’t buying options like this…

There is no options strategy that more perfectly approaches trading the fastest moving and most volatile stocks available in the marketplace than this one. In fact, there is no strategy that better utilizes put options for optimal returns and a real trading edge over other traders in the exact same market. New options traders fail out at an incredible rate without proper trade research, execution timing, and option picking. Capitalize on Schaeffer’s 100+ years of options trading excellence with the most coveted product launch in company history. Don't waste another second... join us right now before the next round of trades are released!

 


 


 
Special Offers from Schaeffer's Trading Partners